The authors propose the O-VAS /N-VAS system, a modification to the existing VAS that enables clinicians to distinguish and analyze post-procedure improvements in symptoms of the original disease while also assessing new symptoms.
The authors propose the O-VAS /N-VAS system, a modification to the existing VAS that enables clinicians to distinguish and analyze post-procedure improvements in symptoms of the original disease while also assessing new symptoms.
John Blebea, MD, MBA, from the Central Michigan University College of Medicine in Saginaw, Michigan, discusses latest position statement of the AVLS on mechanical occlusion chemically assisted ablation.
John Blebea, MD, MBA, from the Central Michigan University College of Medicine in Saginaw, Michigan, discusses latest position statement of the AVLS on mechanical occlusion chemically assisted ablation.
At AMP 2024, interventional radiologist Bret Wiechmann, MD, discussed his presentation on the OEIS Registry, which details outcomes within outpatient interventional suites to promote quality and identify benchmarks for best practices.
At AMP 2024, interventional radiologist Bret Wiechmann, MD, discussed his presentation on the OEIS Registry, which details outcomes within outpatient interventional suites to promote quality and identify benchmarks for best practices.
The Symplicity Spyral RDN system, approved by the U.S. FDA in November 2023, is an innovative, minimally invasive procedure that delivers radiofrequency energy to nerves near the kidneys that can become overactive and contribute to high blood...
The Symplicity Spyral RDN system, approved by the U.S. FDA in November 2023, is an innovative, minimally invasive procedure that delivers radiofrequency energy to nerves near the kidneys that can become overactive and contribute to high blood...
Peer-reviewed data highlights successful clinical study with 35.5% clot burden reduction, validating the safety, efficacy, and efficiency of AlphaVac F1885 System in pulmonary embolism treatment.
LATHAM, N.Y.--(BUSINESS WIRE)--Jan. 13,...
Peer-reviewed data highlights successful clinical study with 35.5% clot burden reduction, validating the safety, efficacy, and efficiency of AlphaVac F1885 System in pulmonary embolism treatment.
LATHAM, N.Y.--(BUSINESS WIRE)--Jan. 13,...
MENLO PARK, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Inquis Medical, a leading innovator in venous thromboembolic disease treatment, today announced completion of patient enrollment in its AVENTUS Clinical Trial, a pivotal Investigational...
MENLO PARK, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Inquis Medical, a leading innovator in venous thromboembolic disease treatment, today announced completion of patient enrollment in its AVENTUS Clinical Trial, a pivotal Investigational...
Eric A. Secemsky, MD, MSc, lead investigator for the ELITE-BTK pivotal trial, said, “R3 Vascular’s novel approach in the design of its next generation bioresorbable drug eluting scaffold is of great interest to the physician community and has...
Eric A. Secemsky, MD, MSc, lead investigator for the ELITE-BTK pivotal trial, said, “R3 Vascular’s novel approach in the design of its next generation bioresorbable drug eluting scaffold is of great interest to the physician community and has...
Clinicians from Germany, Dubai, Japan, U.S., Switzerland among scrub-in and live case transmissions; educational program features 500+ vascular, endovascular presentations.
MALVERN PA., (January 13, 2024) — First-to-podium data...
Clinicians from Germany, Dubai, Japan, U.S., Switzerland among scrub-in and live case transmissions; educational program features 500+ vascular, endovascular presentations.
MALVERN PA., (January 13, 2024) — First-to-podium data...
This agreement includes Contego Medical’s portfolio of commercially available products, including the recently FDA approved Neuroguard IEP® System, a unique 3-in-1 carotid stenting system that combines a high-performance stent, post-dilation...
This agreement includes Contego Medical’s portfolio of commercially available products, including the recently FDA approved Neuroguard IEP® System, a unique 3-in-1 carotid stenting system that combines a high-performance stent, post-dilation...
Data showcased in two late-breaking clinical trial presentations at Paris Vascular Insights Course
PARIS – December 13, 2024 – Sensome, the pioneer of microsensing technology for instant intra-operative tissue analysis, today announced...
Data showcased in two late-breaking clinical trial presentations at Paris Vascular Insights Course
PARIS – December 13, 2024 – Sensome, the pioneer of microsensing technology for instant intra-operative tissue analysis, today announced...
The integration follows the completion of a successful trial of EchoSolv-AS at Beth Israel in September 2024, in which BIDMC researchers validated the technology’s key performance metrics.
The integration follows the completion of a successful trial of EchoSolv-AS at Beth Israel in September 2024, in which BIDMC researchers validated the technology’s key performance metrics.
“With the 200 cm length, the R2P NaviCross catheter provides physicians performing percutaneous transluminal endovascular procedures from the radial artery a valuable tool to enhance their ability to safely and efficiently complete more...
“With the 200 cm length, the R2P NaviCross catheter provides physicians performing percutaneous transluminal endovascular procedures from the radial artery a valuable tool to enhance their ability to safely and efficiently complete more...
Hechingen, November 26th, 2024 -- Shortly after receiving the CE certification for its BeFlared Stent Graft System, the world’s first dedicated bridging stent for fenestrated endovascular aneurysm repair (FEVAR), Bentley announced the...
Hechingen, November 26th, 2024 -- Shortly after receiving the CE certification for its BeFlared Stent Graft System, the world’s first dedicated bridging stent for fenestrated endovascular aneurysm repair (FEVAR), Bentley announced the...
